yeah, i followed him into the trade as well. i see the CNBC site, and Yahoo, referred to Sanderson Farms instead of Sprouts, so Najarian's mention and the video aren't listed here as news. He called out White Wave two weeks ago, and it was bought out last week. Wish I got into that one, damn it.
yeah, that came out after the release I read from the company. the pricing wasn't in the release.
and the answer is yes: https://www.thestreet.com/story/13622949/1/gilead-sciences-bucks-tradition-takes-low-road-on-new-hepatitis-c-drug-price.html?utm_source=alert&utm_medium=email&utm_campaign=TSC&utm_term=Gilead+Sciences+Bucks+Tradition%2C+Takes+%27Low+Road%27+on+New+Hepatitis+C+Drug+Price
“Today’s approval represents a significant advance for patients with HCV genotypes 2 and 3, who previously required more complex and costly regimens,” said John Milligan...
Is that hinting that this will come in priced below others on the market, including their own drugs, thereby avoiding the headline risk of the new one being perceived as overpriced?
I saw one on that today too, but it said GILD has 60 drugs in P3, which doesn't look even close to correct when you look at their pipeline page. That shows 10 or so.
The last two trial updates have murdered the stock, and the Alzheimer's data won't be in for, what, another year? Seems like dead money and a company that can't seem to land a good trial. Although, this drug was a longshot, so 11% seems a little overdone.
yeah, this has nothing to do with the strength of UA's business, at all. lowered guidance in this case indicates nothing about the actual company.